Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology. Its approach recognizes the opportunities in tumors beyond prostate, thyroid & neuroendocrine targets identified through precision oncology & validated by clinical trials & regulatory approval. RAD101, an F-18 radioisotope developed to image brain metastases is the most advanced asset. It is the subject of Phase II clinical trials. Other candidates and paired targets include RAD202 (HER2) & RAD204 (anti-PD-L1) which are both nanobodies conjugated to Lu-177 for treatment. The pipeline further contains RAD301/302, a theranostic pair targeting aV 6 & preclinical assets targeting B7H3 (RV01) & KLK3 (RAD402). The company is developing candidates in both the US & developed global markets. It collaborates with Lantheus Holdings, MD Anderson (Radiopharm Ventures) & with CROs GenesisCare and MedPace.
